['CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF LAMOTRIGINE OR CONCOMITANT DRUG', 'CLINICAL COMMENT', '\xe2\x86\x93 = DECREASED (INDUCES LAMOTRIGINE GLUCURONIDATION)', '\xe2\x86\x91 = INCREASED (INHIBITS LAMOTRIGINE GLUCURONIDATION)', '? = CONFLICTING DATA', 'ESTROGEN-CONTAINING\xc2\xa0ORAL\xc2\xa0CONTRACEPTIVE\xc2\xa0PREPARATIONS\xc2\xa0CONTAINING\xc2\xa030\xc2\xa0MCG\xc2\xa0ETHINYLESTRADIOL\xc2\xa0AND\xc2\xa0150\xc2\xa0MCG\xc2\xa0LEVONORGESTREL', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE\xc2\xa0LEVELS\xc2\xa0APPROXIMATELY\xc2\xa050%', '', '\xe2\x86\x93\xc2\xa0LEVONORGESTREL', 'DECREASE\xc2\xa0IN\xc2\xa0LEVONORGESTREL\xc2\xa0COMPONENT\xc2\xa0BY\xc2\xa019%', 'CARBAMAZEPINE\xc2\xa0(CBZ)\xc2\xa0AND\xc2\xa0CBZ\xc2\xa0EPOXIDE', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'ADDITION\xc2\xa0OF\xc2\xa0CARBAMAZEPINE\xc2\xa0DECREASES\xc2\xa0LAMOTRIGINE\xc2\xa0CONCENTRATION\xc2\xa0APPROXIMATELY\xc2\xa040%', '', '?\xc2\xa0CBZ\xc2\xa0EPOXIDE', 'MAY\xc2\xa0INCREASE\xc2\xa0CBZ\xc2\xa0EPOXIDE\xc2\xa0LEVELS.', 'PHENOBARBITAL/PRIMIDONE', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE\xc2\xa0CONCENTRATION\xc2\xa0APPROXIMATELY\xc2\xa040%', 'PHENYTOIN\xc2\xa0(PHT)', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE\xc2\xa0CONCENTRATION\xc2\xa0APPROXIMATELY\xc2\xa040%', 'RIFAMPIN', '\xe2\x86\x93\xc2\xa0LAMOTRIGINE', 'DECREASED\xc2\xa0LAMOTRIGINE\xc2\xa0AUC\xc2\xa0APPROXIMATELY\xc2\xa040%', 'VALPROATE', '\xe2\x86\x91\xc2\xa0LAMOTRIGINE', 'INCREASED\xc2\xa0LAMOTRIGINE\xc2\xa0CONCENTRATIONS\xc2\xa0SLIGHTLY\xc2\xa0MORE\xc2\xa0THAN\xc2\xa02-FOLD', '', '?\xc2\xa0VALPROATE', 'DECREASED\xc2\xa0VALPROATE\xc2\xa0CONCENTRATIONS\xc2\xa0AN\xc2\xa0AVERAGE\xc2\xa0OF\xc2\xa025%\xc2\xa0OVER\xc2\xa0A\xc2\xa03-WEEK\xc2\xa0PERIOD\xc2\xa0THEN\xc2\xa0STABILIZED\xc2\xa0IN\xc2\xa0HEALTHY\xc2\xa0VOLUNTEERS;\xc2\xa0NO\xc2\xa0CHANGE\xc2\xa0IN\xc2\xa0CONTROLLED\xc2\xa0CLINICAL\xc2\xa0TRIALS\xc2\xa0IN\xc2\xa0EPILEPSY\xc2\xa0PATIENTS.']